SAILIFE

Oct 8 (Reuters) - Sai Life Sciences Ltd SAIE.NS:

• SAI LIFE SCIENCES LTD - ANNOUNCES INTEGRATED CMC PARTNERSHIP

• SAI LIFE SCIENCES LTD - PARTNERSHIP TO ACCELERATE DRUG DEVELOPMENT FOR INNOVATORS

Source text: ID:nBSE4qwtwF

Further company coverage: SAIE.NS

(([email protected];))

Sept 18 (Reuters) - Sai Life Sciences Ltd SAIE.NS:

• OPENED A DEDICATED FACILITY FOR VETERINARY API PRODUCTION, IN BIDAR

Further company coverage: SAIE.NS

(([email protected];;))

** Shares of contract drugmaker Sai Life Sciences SAIE.NS fall 3.7% to 873 rupees

** PE firm TPG preparing to exit SAIE by selling its 14.7% stake via block deals worth 25 bln rupees ($285.7 mln), CNBC-TV18 reports on Monday

** Stake sale at floor price of 860 rupees, report says, about a 5% discount to SAIE's closing price on Monday

** TPG and Sai Life Sciences did not immediately respond to Reuters requests for comment

** Stock up ~21% YTD

($1 = 87.5060 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected];))

June 20 (Reuters) - Sai Life Sciences Ltd SAIE.NS:

• TPG ASIA VII SF PTE SOLD 20.8 MILLION SHARES IN SAI LIFE SCIENCES VIA BLOCK DEALS - BSE DATA

Source text: [ID:]

Further company coverage: SAIE.NS

(([email protected];;))

Corrects paragraph 14 to say India has "committed" not "invested" $2.86 billion

By Rishika Sadam, Kashish Tandon and Bhanvi Satija

HYDERABAD Feb 27 (Reuters) - India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw material imports at a time when many global pharmaceutical firms are counting on the nation to reduce their reliance on China.

India's Contract Research Development and Manufacturing Organisation (CRDMO) sector is at an inflection point, with the potential to grow seven-fold to $22 billion-$25 billion by 2035, according to a report by Boston Consulting Group.

Globally, the market stands at $140 billion-$145 billion.

"The government has to understand that this industry has potential, if not scale, right now," Krishna Kanumuri, CEO and managing director at Sai Life Sciences SAIE.NS, said at an event earlier this week.

India's contract drug manufacturers have gained from global companies' efforts to diversify their supply chain after the pandemic and a U.S. bill that would prohibit federal contracts with certain Chinese biotech firms on national security grounds.

However, India's policies are yet to play catch-up.

For instance, prolonged approval times and regulatory demands tied to certain raw material imports meant Indian firms often require eight to 15 days to initiate projects, while their Chinese peers could do it within three days, according to Vikash Aggarwala, MD and Partner at BCG's healthcare practice.

Industry insiders pushed for more business-friendly policies in the world's fifth-largest economy, which is heavily dependent on China for drug-related raw materials.

Piramal Pharma's PIRM.NS Chairperson Nandini Piramal lamented the lack of customs warehouses at the right locations and related logistics costs, a dearth of cold storage units, and delays tied to the clearance of certain raw material imports.

"All of those, I think, add more friction to the ease of doing business," Piramal told Reuters.

Some others highlighted the delay in approvals due to the lack of a centralized, digital, single-window clearance system.

Syngene's SYNN.NS CEO-designate Peter Bains said the "friction and delay" could be compressed, highlighting it was "a disadvantage that India has against other jurisdictions".

India's health and finance ministries did not respond to Reuters requests seeking comment.

The country, which offers cheap labour and a large talent pool, has already committed over $2.86 billion in the local biotech industry, according to the BCG report. But industry insiders are urging for more.

"I would really pitch for a CRDMO park... with policies where you don't have to go and get permissions from the local drug controller for making changes, where there are easy export and import capabilities," Aragen Life Sciences CEO Manni Kantipudi said.

($1 = 87.3900 Indian rupees)

(Reporting by Rishika Sadam, Kashish Tandon and Bhanvi Satija; Editing by Dhanya Skariachan and Janane Venkatraman)

(([email protected]; 8800437922;))

Adds details paragraph 2 onwards

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot year for companies listing on the stock market.

Anthem, whose services include early-stage drug discovery and drug efficacy testing, said private equity firm True North and drugmaker DavosPharma are among investors who will sell shares in the IPO.

The company will not sell any shares and it did not give any other details on the offering.

The Indian IPO market has been bustling this year, with over 300 companies having raised $17.5 billion as of mid-December, more than double the amount raised last year, LSEG data showed.

That gives it the top spot globally in terms of proceeds and volumes, according to consultancy firm KPMG.

Anthem, which began operations in 2007 and has two manufacturing facilities, is also going public at a time when global drugmakers are turning to India and other markets to limit their reliance on Chinese contractors.

Begaluru-based Anthem also makes active pharmaceutical ingredients (API), which are the main component of a drug, as well as dietary supplements and probiotics.

It competes with the likes of Syngene International SYNN.NS, Divi's Laboratories DIVI.NS and newly-listed Sai Life Sciences SAIE.NS among Indian API makers.

($1 = 85.5720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of One MobiKwik Systems ONEM.NS gain 8.3% to 572 rupees

** Stock surged 86% in trading debut on Wednesday to 518 rupees vs offer price of 279 rupees, valuing the fintech firm at $474 mln

** ONEM only stock among the three listed on Wed to extend gains on Thurs

** ONEM's peers in listing, budget retailer Vishal Mega Mart VSSL.NS and drugmaker Sai Life Sciences SAIE.NS, down 2% each

** ONEM's $67 mln IPO was subscribed 120 times last week with bids worth $4.7 bln

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of fintech firm One MobiKwik Systems ONEM.NS rise 80.2% to 504 rupees in trading debut

** Priced at 440 rupees vs offer price of 279 rupees

** Co received bids for 1.4 bln shares, worth about $4.7 bln, compared to the 11.9 mln shares on offer

** India's digital payments and financial services market offers significant long-term growth opportunities - KR Choksey Research

** Adds, co's strategic shift towards higher-margin financial services capitalized on established payment user base

** However, the brokerage says ONEM lags in registered user base and diversified service offerings vs peers PhonePe and Paytm

** Budget retailer Vishal Mega Mart VSSL.NS and pharma co Sai Life Sciences SAIE.NS, which also debuted today, opened 33% and 18.4% higher, respectively

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))